Travere Therapeutics, Inc. (TVTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Travere Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Travere Therapeutics, Inc. (TVTX) has returned -22.25% so far this year and 65.79% over the past 12 months. Over the last ten years, TVTX has returned 7.53% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Nov 8, 2012, TVTX's average daily return is +0.23%, while the average monthly return is +3.60%. At this rate, your investment would double in approximately 1.6 years.

Historically, 53% of months were positive and 47% were negative. The best month was Mar 2015 with a return of +69.2%, while the worst month was May 2021 at -38.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, TVTX closed higher 49% of trading days. The best single day was Dec 17, 2012 with a return of +207.6%, while the worst single day was Dec 12, 2012 at -46.8%.

Travere Therapeutics, Inc. has an annualized alpha of 53.49%, beta of 1.18, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 09, 2012.

• This stock captured 170.99% of S&P 500 Index gains and 116.25% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TVTX ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Travere Therapeutics, Inc. (TVTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Travere Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Travere Therapeutics, Inc. was 85.43%, occurring on Apr 26, 2024. Recovery took 387 trading sessions.

The current Travere Therapeutics, Inc. drawdown is 26.24%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Travere Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Travere Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.